NCT01198795 - Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

April 30, 2013

Conditions

Major Depressive Disorder

Interventions

DRUG

Escitalopram

Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.

Trial Locations (16)

19139

Forest Investigative Site 003, Philadelphia

30308

Forest Investigative Site 017, Atlanta

32250

Forest Investigative Site 013, Jacksonville Beach

36303

Forest Investigative Site 001, Dothan

44106

Forest Investigative Site 002, Cleveland

63141

Forest Investigative Site 011, Creve Coeur

66211

Forest Investigative Site 004, Overland Park

68131

Forest Investigative Site 007, Omaha

73116

Forest Investigative Site 012, Oklahoma City

75235

Forest Investigative Site 010, Dallas

84015

Forest Investigative Site 014, Clinton

92108

Forest Investigative Site 006, San Diego

92701

Forest Investigative Site 018, Santa Ana

98007

Forest Investigative Site 005, Bellevue

98033

Forest Investigative Site 015, Kirkland

20010-2970

Forest Investigative Site 008, Washington D.C.